David J. McConkey PhD
Director, Johns Hopkins Greenberg Bladder Cancer Institute; Professor, Brady Urological Institute, Johns Hopkins, Baltimore, MarylandDavid J. McConkey, PhD, is a Professor in the Departments of Urology and Cancer Biology and Director of Urological Research at U.T. M.D. Anderson Cancer Center. He also serves as co-Principal Investigator of the MD Anderson SPORE in Bladder Cancer, Chair for Translational Medicine for the Genitourinary Cancers Committee of the Southwest Oncology Group (SWOG), and a member of the Bladder Cancer Advocacy Network’s (BCAN’s) Bladder Cancer Genomics Consortium (BCGC) Advisory Committee. His research interests are focused on using genomics to identify the molecular mechanisms underlying bladder cancer heterogeneity and to use this information to transform the clinical management of patients with bladder cancer.
Recent Contributions to PracticeUpdate:
- Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes
- Elucidating Prostate Cancer Behavior During Treatment via Low-Pass Whole-Genome Sequencing of ctDNA
- Molecular Correlates of Cisplatin-Based Chemotherapy Response in MIBC
- Cancer Susceptibility Mutations in Patients With Urothelial Malignancies
- Early Detection and Monitoring of Urothelial Bladder Carcinoma by Ultra-Deep Sequencing of ctDNA
- Genomic Differences Between "Primary" and "Secondary" Muscle-Invasive Bladder Cancer and Neoadjuvant Chemotherapy Outcomes
- Liquid Biopsies for Bladder Cancer Surveillance: Success Is in Sight
- Liquid Biopsy Analysis of FGFR3 and PIK3CA Hotspot Mutations for Disease Surveillance in Bladder Cancer
- Urine DNA Testing for Detecting Bladder Cancer in Patients With Gross Hematuria
- Gene Expression Profile of the Clinically Aggressive Micropapillary Variant of Bladder Cancer